Effect of corticosteroid therapy on levels of antibody to hepatitis B core antigen in patients with chronic type B hepatitis

Serum levels of antibody to hepatitis B core antigen and IgM antibody to hepatitis B core antigen were tested in 15 patients who participated in a randomized, placebo‐controlled trial of a 28‐day course of prednisolone therapy. During treatment, serum levels of antibody to hepatitis B core antigen and IgM antibody to hepatitis B core antigen decreased in all 10 treated patients, but in none of five controls (p < 0.05). Also during therapy, ALT activity decreased by an average of 50% and serum IgG levels by 30% (both p <: 0.05). Serum levels of hepatitis B virus DNA and DNA polymerase activity did not change significantly. Four to 10 weeks after discontinuation of prednisolone, a rebound of serum ALT and IgM antibody to hepatitis B core antigen levels occurred, which usually resolved within the subsequent months of follow‐up evaluation. In three patients, however, there was a prolonged exacerbation of the disease following prednisolone withdrawal; in these three, levels of IgM antibody to hepatitis B core antigen and ALT remained elevated above pretreatment values. The close correlation between changes in serum ALT activity and IgM antibody to hepatitis B core antigen levels suggests that corticosteroids can modulate disease activity in chronic type B hepatitis by suppression of the host‐immune response to hepatitis B virus antigens.

[1]  J. Hoofnagle,et al.  A short course of prednisolone in chronic type B hepatitis. Report of a randomized, double-blind, placebo-controlled trial. , 2020, Annals of internal medicine.

[2]  M. Tong,et al.  Effects of short-term, high-dose prednisone treatment of patients with HBsAg-positive chronic active hepatitis. , 2008, Liver.

[3]  D. Shafritz,et al.  Analysis of Liver Disease, Nuclear HBcAg, Viral Replication, and Hepatitis B Virus DNA in Liver and Serum of HBcAg Vs. Anti‐HBe Positive Carriers of Hepatitis B Virus , 2007, Hepatology.

[4]  L. Bianchi,et al.  Prevalence and Significance of Anti‐HBc IgM (Radioimmunoassay) in Acute and Chronic Hepatitis B and in Blood Donors , 2007, Hepatology.

[5]  L. Overby,et al.  Serodiagnosis of Recent Hepatitis B Infection by IgM Class Anti‐HBc , 2007, Hepatology.

[6]  J. Hoofnagle,et al.  Effects of immunosuppressive therapy with prednisolone on B and T lymphocyte function in patients with chronic type B hepatitis , 1986, Hepatology.

[7]  J. Hoofnagle,et al.  Immunoglobulin M antibody to hepatitis B core antigen in patients with chronic type B hepatitis. , 1985, Gastroenterology.

[8]  M. Tong,et al.  Detection of Anti‐HBc IgM Following Prednisone Treatment in Patients with Chronic Active Hepatitis B Virus Infection , 1984, Hepatology.

[9]  F. Tsuda,et al.  Low molecular weight (7s) immunoglobulin M antibody against hepatitis B core antigen in the serum for differentiating acute from persistent hepatitis B virus infection , 1984 .

[10]  S. Lemon,et al.  Low-molecular-weight IgM antibody to hepatitis B core antigen in chronic infections with hepatitis B virus. , 1983, The Journal of infectious diseases.

[11]  F. Tsuda,et al.  Immunoglobulin M Antibody Against Hepatitis B Core Antigen for the Diagnosis of Fulminant Type B Hepatitis , 1983 .

[12]  T. Merigan,et al.  Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B. , 1981, Gastroenterology.

[13]  W. Bancroft,et al.  IgM antibody to hepatitis B core antigen as a diagnostic parameter of acute infection with hepatitis B virus. , 1981, The Journal of infectious diseases.

[14]  J. Nielsen,et al.  Presence and meaning of anti‐HBc IgM as determined by ELISA in patients with acute type B hepatitis and healthy HBsAg carriers , 1981, Hepatology.

[15]  E. Sagnelli,et al.  SERUM LEVELS OF HEPATITIS B SURFACE AND CORE ANTIGENS DURING IMMUNOSUPPRESSIVE TREATMENT OF HBsAg-POSITIVE CHRONIC ACTIVE HEPATITIS , 1980, The Lancet.

[16]  B. J. Winer.  Single-factor experiments having repeated measures on the same elements. , 1962 .